[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"diabetic-peripheral-neuropathy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:diabetic-peripheral-neuropathy":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,25,0,[8,46,71,94,113,139,167,194,219,245,268,296,321,341,363,387,414,437,458,481,515,538,563,585,616],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":4},"100644505","efficacy-of-a-structured-multisensory-re-education-program-on-sensory-function-and-upper-limb-sensorimotor-performance-in-individuals-with-diabetic-peripheral-neuropathy-100644505",false,"NCT07670598","Efficacy of a Structured Multisensory Re-education Program on Sensory Function and Upper Limb Sensorimotor Performance in Individuals With Diabetic Peripheral Neuropathy.","Efficacy of a Structured Multisensory Re-education Program on Sensory Function and Upper Limb Sensorimotor Performance in Individuals With Diabetic Peripheral Neuropathy: A Randomized Sham-Controlled Trial.","SENS-UL","InclusioInclusion Criteria:\n\nAdults aged 18 to 75 years. Clinically confirmed diabetic peripheral neuropathy (DPN). Stable medical condition and medication regimen for at least 3 months. Ability to understand study procedures and provide informed consent. Ability to participate in upper-limb sensory and sensorimotor assessments. Willingness to attend all intervention sessions and follow study instructions.\n\nExclusion Criteria:\n\nOther neurological disorders affecting sensory or motor function (e.g., stroke, multiple sclerosis, Parkinson's disease).\n\nSevere visual, auditory, or cognitive impairment interfering with participation.\n\nUpper-limb musculoskeletal conditions limiting hand function or assessment performance.\n\nActive foot ulcer, severe diabetic complications, or unstable medical condition.\n\nParticipation in another rehabilitation or clinical trial during the study period.\n\nPregnancy.\n\nInability to comply with study procedures or follow-up assessments.n Criteria:\n\nExclusion Criteria:\n\n\\-","ALL","18 Years","75 Years",{"count":21,"type":22},59,"ESTIMATED","INTERVENTIONAL",[25],"NA","Diabetic Peripheral Neuropathy (DPN) is a common complication of diabetes that can cause impairments in sensation, dexterity, and upper-limb function. Current treatment approaches mainly focus on symptom management and glycemic control, while interventions specifically targeting sensory recovery remain limited.\n\nThis randomized sham-controlled trial aims to evaluate the effectiveness of a Structured Multisensory Re-education Program (SENS-UL) in improving sensory function and upper-limb sensorimotor performance in adults with DPN. Participants will be randomly assigned to either an intervention group receiving structured multisensory sensory re-education or a sham-control group receiving passive sensory exposure without active sensory retraining.\n\nThe intervention will be delivered twice weekly for five weeks. Outcome measures will include sensory function, neuropathy severity, thermal and tactile sensation, vibration perception, proprioception, dexterity, and neuropathy-related quality of life. Assessments will be conducted before and after the intervention period.\n\nThe study is expected to provide evidence regarding the effectiveness of multisensory sensory rehabilitation for individuals with DPN and may contribute to the development of targeted rehabilitation strategies aimed at improving sensory recovery, hand function, and quality of life.",[28],"Diabetic Peripheral Neuropathy",[30,31,32,33],"Multisensory Rehabilitation","Sensorimotor Function","Upper Limb Function","Quality of Life","NOT_YET_RECRUITING","2026-06-25",{"date":37,"type":38},"2026-06-26","ACTUAL",{"date":40,"type":22},"2026-09-01",{"date":42,"type":22},"2028-09-30",{"name":44,"class":45},"Imam Abdulrahman Al Faisal Hospital","OTHER_GOV",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":70},"100641440","shortwave-intervention-for-diabetic-peripheral-neuropathy-100641440","NCT07625007","Shortwave Intervention for Diabetic Peripheral Neuropathy.","Shortwave Intervention for Diabetic Peripheral Neuropathy: A Randomized, Single-Blind, Sham-Controlled Trial(SIDPN)","Inclusion Criteria:\n\n* 1\\. Aged 18-85 years, regardless of gender, with the ability to act independently;\n* 2\\. Appearance of neuropathic symptoms or signs at the time of or after the diagnosis of diabetes, meeting the following criteria: presence of DPN symptoms (numbness, tingling, burning, cold, pain), with or without signs (abnormalities in any of ankle reflex, vibration sense, pinprick sensation, temperature sensation, or pressure sensation);\n* 3\\. Able to complete the TCSS assessment;\n* 4\\. Understands the entire trial process, voluntarily participates in the study, and signs the informed consent form.\n* 5\\. Patients who did not respond to adequate treatment with mecobalamin and other medications.\n\nExclusion Criteria:\n\n* 1\\. Peripheral neuropathy caused by other reasons (such as lumbar spine lesions, vitamin B12 deficiency, uncontrolled hypothyroidism, alcohol intoxication, drug neurotoxicity, Guillain-Barré syndrome, etc.);\n* 2\\. Hemorrhagic diseases, malignant tumors;\n* 3\\. History of below-knee amputation;\n* 4\\. Skin damage, infection at the treatment site, or presence of metal implants, pacemaker;\n* 5\\. Combined severe heart, liver, or kidney dysfunction (e.g., eGFR \\\u003C 15 ml\u002Fmin\u002F1.73m²), or cognitive impairment preventing cooperation;\n* 6\\. Pregnancy, breastfeeding, or planning pregnancy;\n* 7\\. Participation in other interventional clinical trials within the past 3 months;\n* 8\\. Combined severe psychiatric disorders;\n* 9\\. Other conditions assessed by the investigator that prevent completion of the trial;\n* 10\\. Poor compliance.","85 Years",{"count":55,"type":22},202,[25],"This study is a single-center, randomized, single-blind, sham-controlled clinical trial aimed at evaluating the efficacy and safety of shortwave therapy administered for five consecutive days in the treatment of diabetic peripheral neuropathy. The study plans to enroll 202 patients, who will be randomly assigned in a 1:1 ratio to either the shortwave therapy group (20 minutes daily for five consecutive days) or a sham treatment group with an identical appearance. The primary efficacy endpoint is the remission rate of the Toronto Clinical Scoring System score one month after treatment (a decrease of ≥1 point). Secondary endpoints include short-term efficacy, pain visual analog scale scores, quality of life scores, and safety indicators. The study hypothesizes that shortwave therapy can significantly improve neurological symptoms, with an expected remission rate of 65% in the treatment group and 20% in the control group, with the superiority margin set at 20%. This study will provide high-quality evidence-based medical evidence for the use of shortwave therapy in diabetic peripheral neuropathy.",[28],"RECRUITING","2026-06-16",{"date":62,"type":38},"2026-06-18",{"date":64,"type":22},"2026-05-20",{"date":66,"type":22},"2027-05-20",{"name":68,"class":69},"Chongqing Medical University","OTHER",1,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":53,"enrollmentInfo":79,"targetDuration":4,"studyType":23,"phases":81,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":92,"leadSponsor":93,"locationsCount":70},"100641528","ultrasound-guided-nerve-hydrodissection-for-diabetic-lower-limb-entrapment-neuropathy-100641528","NCT07625020","Ultrasound-Guided Nerve Hydrodissection for Diabetic Lower Limb Entrapment Neuropathy","Ultrasound-Guided Nerve Hydrodissection for Diabetic Lower Limb Entrapment Neuropathy: A Randomized, Single-Blind, Sham-Controlled Trial","HUND","Inclusion Criteria:\n\n1. Age 18-85 years, male or female;\n2. Diagnosis of DLLEN meeting the following criteria: ① Clinical diagnosis of DPN (presence of DPN clinical symptoms plus at least one positive physical sign, or absence of symptoms but presence of two or more positive physical signs), with other etiologies excluded; ② Presence of unilateral or bilateral lower limb symptoms suggestive of peripheral nerve entrapment, including hypoesthesia\u002Fparesthesia in a specific nerve distribution area, pain and\u002For motor dysfunction, or a positive Tinel sign at the corresponding site; ③ Physical examination findings such as decreased or absent skin sensation in the corresponding nerve distribution area, reduced or absent strength of ankle dorsiflexion or eversion, metatarsophalangeal joint movement disorder, foot drop, or foot inversion; ④ Electrophysiological study showing slowing or blockade of nerve conduction velocity at a specific site (across a narrowed segment); ⑤ Imaging study (nerve ultrasound) showing compression of the corresponding nerve (cross-sectional area at the entrapment site exceeding the upper limit of the reference range, decreased nerve echogenicity, or swelling of the nerve fascicles). Diagnosis requires fulfillment of ①, ②, and ③, plus either ④ or ⑤;\n3. Inadequate response to adequate treatment with medications such as mecobalamin and α-lipoic acid;\n4. Understanding of the entire study process and voluntary provision of written informed consent.\n\nExclusion Criteria:\n\n1. Presence of another clearly identified etiology assessed by the investigator as the primary cause of the patient's current lower limb neurological symptoms, including but not limited to: cervical or lumbar spine disease (e.g., radicular symptoms or sciatica), lower extremity vascular disease, cerebral infarction, thyroid dysfunction, vitamin B12 deficiency, heavy alcohol use history, recent chemotherapy or radiotherapy, drug toxicity, or other non-diabetic causes of neuropathy (e.g., CIDP, cauda equina syndrome, subacute combined degeneration of the spinal cord, Guillain-Barré syndrome);\n2. Concurrent malignancy, active systemic infection, or immune system disease;\n3. Lower limb edema due to any cause;\n4. Skin breakdown or infection at the treatment site below the knee;\n5. Severe cardiac, hepatic, or renal insufficiency (eGFR \\\u003C30 mL\u002Fmin\u002F1.73m², liver transaminases \\>2.5 times the upper limit of normal, or New York Heart Association functional class ≥II);\n6. Cognitive impairment or severe mental illness;\n7. Pregnancy or breastfeeding;\n8. Participation in another interventional clinical trial within the past 3 months;\n9. Poor compliance, assessed as unlikely to complete the study per protocol;\n10. Any other condition assessed by the investigator as making the patient unsuitable to complete the trial.",{"count":80,"type":22},266,[25],"The goal of this clinical trial is to learn if a single session of ultrasound-guided nerve hydrodissection can relieve symptoms of diabetic lower limb entrapment neuropathy, a condition caused by compressed nerves in the leg that leads to numbness, pain, or muscle weakness in people with diabetes. The main questions it aims to answer are whether nerve hydrodissection improves nerve function (measured by the Toronto Clinical Scoring System) one month after treatment, and whether it relieves pain and improves quality of life. Researchers will compare two groups: one will receive the actual nerve hydrodissection (injection of medicine around the compressed nerve), and the other will receive a sham procedure that involves injecting a small amount of fluid under the skin (not around the nerve). Participants will not know which group they are in, and the researchers who measure the results will also not know. Participants will have four in-person visits over about one month, complete questionnaires about their nerve symptoms, pain, and quality of life, undergo nerve ultrasound at the beginning and at follow-up visits (at 1 month after treatment), and receive either the nerve hydrodissection or the sham procedure at the second visit. All participants will continue their regular diabetes and nerve medication during the study.",[28,84],"Entrapment Neuropathy",[86,84,87],"Diabetic peripheral neuropathy","Nerve Hydrodissection","2026-06-15",{"date":90,"type":38},"2026-06-17",{"date":64,"type":22},{"date":66,"type":22},{"name":68,"class":69},{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":23,"phases":103,"briefSummary":104,"conditions":105,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":106,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":70},"100538200","spinal-cord-stimulation-and-small-fiber-peripheral-neuropathy-100538200","NCT06287736","Spinal Cord Stimulation and Small Fiber Peripheral Neuropathy","A Novel Neuromodulation Approach to Target Small Fiber Neuropathy Early in Diabetes and Measure Functional Recovery","Inclusion Criteria:\n\n* Over 18 years old\n* Diagnosis of diabetic peripheral neuropathy refractory to treatment with gabapentin or pregabalin and at least 1 other class of analgesic\n* Diagnosis of medically refractory pain secondary to diabetic neuropathy\n* Presence of pain for 12 months\n* Lower limb pain intensity score ≥4 on a visual analog scale\n* DN4 ≥4\n* Pass pre-operative neuropsychological assessment (surgical group only)\n* Capable of providing informed consent\n\nExclusion Criteria:\n\n* Severe medical comorbidities that, in the opinion of the surgeon, exclude the patient from surgical intervention\n* Spinal disease with severe spinal stenosis or spinal cord compression in the region of the proposed spinal cord stimulator lead placement\n* Coagulopathy that cannot be corrected\n* Unable to discontinue blood thinning medications\n* Hemoglobin A1c level greater than 10\n* Presence of systemic infection\n* Pregnancy",{"count":102,"type":22},60,[25],"This is a prospective randomized control trial. Participants enrolled into the study will be randomized into one of three groups, two of which are treatment groups and the third is a control group. A time course of measurements before and after spinal cord stimulation (SCS) treatment (where applicable) will assess pain, DPN severity, small fiber nerve activity, and metabolic health markers.",[28],{"date":90,"type":38},{"date":108,"type":38},"2024-04-17",{"date":110,"type":22},"2029-12-31",{"name":112,"class":69},"Ohio State University",{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":23,"phases":121,"briefSummary":122,"conditions":123,"keywords":125,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":70},"100413063","functional-and-neuroprotective-effects-of-restoring-lower-limb-sensation-after-diabetic-peripheral-neuropathy-100413063","NCT04658693","Functional and Neuroprotective Effects of Restoring Lower Limb Sensation After Diabetic Peripheral Neuropathy","Inclusion Criteria:\n\n* Chronic, medically stable lower limb amputation due to diabetes or insensate foot due to Diabetic peripheral neuropathy\n* Being ambulatory and ability to stand or walk with prosthesis or orthosis\n* Viable target nerves in the lower extremity as determined by standard-of-care clinical tests of nerve conduction, response to stimulation, sensory evoked potentials (SEP) and the like\n* Good skin integrity and personal hygiene\n* Absence of autoimmune deficiencies, seizure disorders or cardiac abnormalities contraindicating stimulation\n* Sufficient social support and personal ability to tolerate study procedures and comply with follow-up schedule\n\nExclusion Criteria:\n\n* Active pressure ulcers or chronic skin ulcerations\n* Uncontrolled diabetes with HbA1c greater than or equal to 69 mmol\u002Fmol (8.5%)\n* Significant vascular disease\n* Significant history of poor wound healing\n* Significant history of uncontrolled infections\n* Active infection\n* Significant pain in the foot, residual or phantom limb\n* Pregnancy\n* Inability to speak English: The study design requires the subject to communicate and describe the elicited sensations in their lower limb\n* History of vestibular or movement disorders that would compromise balance or walking\n* Class II or III obesity (Body Mass Index \\> 35)\n* Uncontrolled depression, psychoses or cognitive impairments. Subjects with unstable mental illness or severe cognitive impairments may be unable to comply with a long term study schedule\n* Expectation that MRI will be required at any point for the duration of study or while percutaneous leads are in place. At this time MRI is contraindicated, subjects who require regular MRI should not enroll\n* Arthritis in the area of implant- Inflammation or stiffness in the area of implant could limit placement of the electrodes",{"count":120,"type":22},15,[25],"The purpose of this study is to evaluate the effectiveness of providing sensation of the missing limb to individuals with above and below the knee limb loss. The investigators will implanted stimulating electrodes to send small electrical currents to the remaining nerves. These small electrical currents cause the nerves to generate signals that are then transferred to your brain similar to how the information about your foot and lower limb used to be transferred to the brain prior to your limb loss. Additionally, there is the option to have muscle recording electrodes implanted within the muscles of the lower limb with the goal to develop a motor controller that would allow the user to have intuitive control of a robotic prosthetic leg.",[124,28],"Lower Extremity Amputee",[126,127,128],"Sensory Feedback","Limb Loss","Prosthesis User","2026-06-02",{"date":131,"type":38},"2026-06-04",{"date":133,"type":38},"2021-03-02",{"date":135,"type":22},"2031-05-30",{"name":137,"class":138},"VA Office of Research and Development","FED",{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":146,"minAge":147,"maxAge":148,"enrollmentInfo":149,"targetDuration":4,"studyType":23,"phases":151,"briefSummary":152,"conditions":153,"keywords":154,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":70},"100637893","comparison-of-otago-and-beat-it-program-on-balance-gait-and-qol-in-diabetic-neuropathy-100637893","NCT07575113","Comparison of Otago and Beat it Program on Balance, Gait and QOL in Diabetic Neuropathy","Comparative Effects of Otago Exercise Program and Beat it Program on Balance, Gait and Quality of Life in Patients With Diabetic Peripheral Neuropathy","Inclusion Criteria:\n\n* physician-diagnosed type 2 diabetes, with peripheral neuropathy (defined by Michigan Neuropathy Screening Instrument questionnaire score of 5 or greater) the ability to walk independently for 20 m (97).\n* Having score between 46 to 52 (out of a total of 56 points) on the BBS\n\nExclusion Criteria:\n\n* fracture of the lower limb within the 6 months before the study\n* diabetic ulcer, infection or partial amputation in feet\n* disease or functional impairment of auditory, vestibular system\n* Dementia or inability to give consistent information\n* History of surgical procedure at the knee, ankle, or hip or indication of surgery throughout the intervention period malignancy, other neurological or orthopedic impairments (such as stroke, poliomyelitis, rheumatoid arthritis, prosthesis, or severe osteoarthritis), major vascular complications (venous or arterial ulcers), severe retinopathy, or severe nephropathy that causes edema or needs hemodialysis","FEMALE","45 Years","65 Years",{"count":150,"type":22},32,[25],"this study aims to compare the effects of Otago exercise program and BEAT IT program on balance, gait and quality of life in patients with diabetic peripheral neuropathy.",[28],[155,156,157,28],"Balance","Gait","Quality of life","2026-05-04",{"date":160,"type":38},"2026-05-08",{"date":162,"type":22},"2026-05-15",{"date":164,"type":22},"2026-09-15",{"name":166,"class":69},"Riphah International University",{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":4,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":17,"minAge":174,"maxAge":19,"enrollmentInfo":175,"targetDuration":4,"studyType":23,"phases":177,"briefSummary":179,"conditions":180,"keywords":183,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":70},"100612982","early-phase-1-efficacy-of-a-topical-palmitated-formulation-of-capsaicin-capsadyn-in-the-treatment-of-diabetic-neuropathic-foot-pain-100612982","NCT07260656","Efficacy of a Topical Palmitated Formulation of Capsaicin (Capsadyn®) In the Treatment of Diabetic Neuropathic Foot Pain","A Double-Blind, Randomized, Pilot Study to Investigate the Efficacy of a Topical Palmitated Formulation of Capsaicin (Capsadyn®) In the Treatment of Diabetic Neuropathic Foot Pain","Inclusion Criteria:\n\n* At least 3 toes per foot\n* Have otherwise intact feet.\n* Absence of any eczema, hyperkeratosis, scleroderma, or other dermatological conditions afflicting the area of Test Article administration that may interfere with absorption, particularly hyperhidrosis.\n* Must agree to apply the Test Article to painful areas of feet as directed by research personnel.\n* Must agree to apply the Test Article to feet as instructed 2x per day.\n* Must wait 60 minutes after each application of Test Article before filling out NRS forms.\n* Unless burning is encountered soon after application, the participant must wait at least 60 minutes before washing feet after application of Test Article.\n* All participants must be willing to use Test Articles blinded.\n\nExclusion Criteria:\n\n* Younger than 25 and older than 75 years of age\n* Any dermatological condition(s) with the potential to disrupt skin integrity or alter sensory function of the feet.\n* Any open wounds, skin ulceration, infection, skin irritation (e.g., poison oak), history of eczema, trauma or burn (including sunburn) affecting the feet within 30 days.\n* Any recent medical history of surgery affecting the feet.\n* Unless part of a stable continuum of substance use prior to start of study, the use of any topical medication products on feet, including holistic formulations, patch or herbal products, cannabinoid products, prescription or over the-counter (OTC) analgesic creams\u002Flotions\u002Fpatches\u002Fgels, nonsteroidal anti-inflammatory drugs, acetaminophen, counterirritants, local anesthetics, or steroids is prohibited.\n* Current substance abuse.\n* History of hypersensitivity or allergy to chili peppers, coconut oil, Shea butter, or sunflower seed oil.\n* Except for interventions for mobility, (e.g., physical therapy, exercise, grounding) no concurrent foot therapy for pain that may interfere with NRS evaluations is permitted (e.g., massage, electrophoresis, red light, etc.).\n* No concurrent enrollment in another clinical trial.","25 Years",{"count":176,"type":22},80,[178],"EARLY_PHASE1","The purpose of this research is to assess whether the use of a topical cream with an active ingredient can reduce the amount of foot pain experienced in participants who have been diagnosed with Diabetic Peripheral Neuropathy (DPN) with minimal side effects or discomfort from use.",[181,182,28],"Diabetic Neuropathies, Painful","Diabetic Foot",[184],"diabetic foot pain","2026-04-15",{"date":187,"type":38},"2026-04-20",{"date":189,"type":38},"2025-11-26",{"date":191,"type":22},"2027-11",{"name":193,"class":69},"Carilion Clinic",{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":198,"acronym":4,"eligibilityCriteria":199,"healthyVolunteers":11,"sex":17,"minAge":147,"maxAge":200,"enrollmentInfo":201,"targetDuration":4,"studyType":23,"phases":202,"briefSummary":203,"conditions":204,"keywords":206,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":70},"100561562","innovative-multi-variable-biofeedback-for-improving-gait-performance-in-individuals-with-diabetic-peripheral-neuropathy-100561562","NCT06591780","Innovative Multi-Variable Biofeedback for Improving Gait Performance in Individuals With Diabetic Peripheral Neuropathy","Inclusion Criteria:\n\n* Able to walk 10-meters independently without an assistive device\n* Sufficient cardiovascular and musculoskeletal health to walk on a treadmill for 6 minutes at a self-selected speed\n* Diagnosis of diabetes mellitus\n* Diagnosis of diabetic peripheral neuropathy by a physician\n* Foot examination within the past 6 months documenting ambulatory status\n* Physician clearance\n\nExclusion Criteria:\n\n* History of amputation\n* Active ulceration\n* Medial column deformity\n* Severe cognitive impairment (MoCA \\< 10)\n* Severe visual impairment\n* History of Charcot osteoarthropathy\n* History of posterior muscle group lengthening\n* History of lower extremity joint replacement\n* History of lower extremity and\u002For foot surgery affecting walking mechanics\n* Orthopaedic problems of the lower limbs or spine due to other medical conditions (not diabetes or DPN) that limit walking or cause pain during walking\n* Improper footwear for walking and community ambulation\n* Cardiovascular or medical condition affecting ability to walk safely\n* History of unexplained dizziness or fainting in the past 2 months\n* Allergy to adhesive tape or rubbing alcohol","90 Years",{"count":5,"type":22},[25],"This study aims to collect data to improve gait function in individuals with Diabetic Peripheral Neuropathy (DPN).\n\nThe primary goals are to evaluate:\n\n* Biomechanical mechanisms contributing to abnormal plantar pressure and propulsion during gait in individuals with DPN\n* Biofeedback-induced changes in plantar pressure, propulsion, and biomechanics during gait in individuals with DPN\n\nThe participants will be required to complete\n\n* Questionnaires\n* Clinical examination\n* 3-Dimensional gait analysis on an instrumented treadmill\n* Visual and auditory biofeedback on the participant's propulsion and plantar pressure metrics provided by a projector screen during walking",[28,205],"Diabetes Mellitus",[207,208,209],"anterior ground reaction force","biofeedback-induced changes in plantar pressure","diabetic peripheral neuropathy","2026-03-09",{"date":212,"type":38},"2026-03-11",{"date":214,"type":38},"2025-10-20",{"date":216,"type":22},"2027-06-01",{"name":218,"class":69},"Florida Institute for Human and Machine Cognition",{"id":220,"slug":221,"hasResults":11,"nctId":222,"briefTitle":223,"officialTitle":224,"acronym":225,"eligibilityCriteria":226,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":227,"targetDuration":4,"studyType":229,"phases":4,"briefSummary":230,"conditions":231,"keywords":233,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":70},"100623081","new-diagnostic-tool-minion-for-identifying-microorganisms-in-foot-wounds-of-patients-living-with-diabetic-foot-osteomyelitis-100623081","NCT07391995","New Diagnostic Tool (MinION) for Identifying Microorganisms in Foot Wounds of Patients Living With Diabetic Foot Osteomyelitis","Evaluation of a New Diagnostic Tool (MinION) for Identifying Microorganisms in the Foot Wounds of Patients Living With Diabetic Foot Osteomyelitis (DFOM)","MINI-OS","Inclusion Criteria:\n\n* N\u002FA\n\nExclusion Criteria:\n\n* N\u002FA",{"count":228,"type":22},43,"OBSERVATIONAL","Diabetic foot wound infections are predominantly polymicrobial. However, 'conventional' microbiological culture does not identify all the bacteria potentially involved in these infections and requires time, which can have a negative impact by delaying treatment and\u002For the prescription of appropriate antibiotic therapy.\n\nReal-time metagenomics analysis using Oxford Nanopore Technologies' MinION technology has demonstrated sufficient power to identify virtually all microbial genomes in a given sample, providing additional information on their antibiotic resistance profile and in silico prediction of genes encoding virulence factors within than 4 hours. Based on these rapid results, a management protocol could be defined specifically for each patient with a view to personalised medicine.\n\nThe aim is to study the diversity of bacterial and fungal species identified using the MinION method and compare this diversity with the results obtained using conventional methods (routine culture) from bone biopsies taken from DFOM patients.",[205,232,28],"Diabetes Complications",[234,235],"Foot Ulcer, Diabetic","Infection","2026-02-10",{"date":238,"type":38},"2026-02-11",{"date":240,"type":38},"2026-01-01",{"date":242,"type":22},"2026-12",{"name":244,"class":69},"Centre Hospitalier Universitaire de Nīmes",{"id":246,"slug":247,"hasResults":11,"nctId":248,"briefTitle":249,"officialTitle":249,"acronym":250,"eligibilityCriteria":251,"healthyVolunteers":11,"sex":17,"minAge":252,"maxAge":19,"enrollmentInfo":253,"targetDuration":4,"studyType":23,"phases":254,"briefSummary":255,"conditions":256,"keywords":257,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":263,"completionDateStruct":264,"leadSponsor":266,"locationsCount":70},"100622227","comparison-of-proprioceptive-neuromuscular-training-and-sensory-re-education-in-patients-with-diabetic-peripheral-neuropathy-100622227","NCT07380880","Comparison of Proprioceptive Neuromuscular Training and Sensory Re-education in Patients With Diabetic Peripheral Neuropathy","PNF-SR in DPN","Inclusion Criteria:\n\nBoth males and females Diagnosed with Diabetes Mellitus (Type 1 or Type 2) Aged between 40-75 years Presence of diabetic peripheral neuropathy (as confirmed by Michigan Neuropathy Assessment Tool or Toronto Clinical Rating Scale) HbA1c level \\> 7% consistently over the last 6 months\n\nExclusion Criteria:\n\nUnable to ambulate independently or with assistance Any history of neurological disorders Any history of musculoskeletal disordersin the past 6 months Renal and liver failure History of Ischemic heart disease History of dizziness or balance-impairing conditions","40 Years",{"count":176,"type":22},[25],"Diabetic peripheral neuropathy (DPN) is a common complication of diabetes mellitus and is associated with sensory loss, impaired proprioception, balance deficits, and altered gait patterns, which significantly increase the risk of falls and functional dependence. Rehabilitation strategies targeting sensory and proprioceptive impairments are essential to improve postural control and mobility in this population.\n\nThis randomized controlled trial aims to compare the effects of proprioceptive neuromuscular training and sensory re-education on balance and gait performance in patients with diabetic peripheral neuropathy. Participants diagnosed with DPN will be randomly allocated into two groups. Group A will receive sensory re-education, while Group B will undergo a structured proprioceptive training program. Both groups will also receive baseline conventional treatment.\n\nBalance and gait outcomes will be assessed using the Berg Balance Scale and the Dynamic Gait Index at baseline, mid-intervention, and post-intervention. The findings of this study may help determine the more effective rehabilitation approach for improving balance and gait in individuals with diabetic peripheral neuropathy, thereby reducing fall risk and enhancing functional independence.",[28],[258,259,155,156],"Proprioceptive Neuromuscular Training","Sensory Re-education","2026-01-31",{"date":262,"type":38},"2026-02-03",{"date":236,"type":22},{"date":265,"type":22},"2026-03-31",{"name":267,"class":69},"Montiha Azeem",{"id":269,"slug":270,"hasResults":11,"nctId":271,"briefTitle":272,"officialTitle":273,"acronym":4,"eligibilityCriteria":274,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":275,"targetDuration":4,"studyType":23,"phases":277,"briefSummary":278,"conditions":279,"keywords":280,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":288,"startDateStruct":290,"completionDateStruct":292,"leadSponsor":294,"locationsCount":70},"100615360","exercise-effects-on-pain-sleep-and-depression-in-diabetic-peripheral-neuropathy-100615360","NCT07291596","Exercise Effects on Pain, Sleep and Depression in Diabetic Peripheral Neuropathy","The Effect of Foot-Ankle Exercises on Pain, Sleep Quality and Depression in Individuals With Diabetic Peripheral Neuropathy","Inclusion Criteria:\n\n* 18 years of age and older\n* Diagnosed with diabetic peripheral neuropathy for at least 6 months S-LANSS pain score ≥ 12\n* Able to perform the exercise program\n* Voluntary participation and informed consent\n\nExclusion Criteria:\n\n* Pregnancy\n* Severe cardiovascular or musculoskeletal disease\n* Cognitive impairment preventing participation\n* Receiving physiotherapy or another structured exercise program during the study\n* Any other condition deemed inappropriate by the investigator",{"count":276,"type":22},70,[25],"It is known that the pain experienced by individuals with diabetic neuropathy negatively impacts sleep and quality of life, leading to numerous psychosocial problems such as anxiety and depression. Studies in the literature indicate that exercise, a non-pharmacological method, improves pain and sleep quality in individuals with diabetic neuropathy. However, no studies have been found evaluating the effects of foot-ankle exercises on pain, sleep quality, and depression in individuals with diabetic neuropathy.\n\nThis research aims to examine the effects of foot-ankle exercises on pain, sleep quality, and depression in individuals with diabetic peripheral neuropathy.\n\nThis randomized controlled experimental study will be conducted with 70 individuals with diabetes diagnosed with diabetic neuropathy, registered in the patient information systems of two public hospitals. The foot-ankle exercises will be performed by the patients in their homes, twice a day, three days a week, for eight weeks. The research data are as follows: The Introductory Information Form will be collected using the S-Lanns (Self-Leeds Assessment of Neuropathic Symptoms and Sign) Pain Scale, VAS-Visual Analog Scale, Pittsburgh Sleep Quality Index (PSQI), and Beck Depression Inventory (BDI).\n\nThis study is important because it will determine the effects of foot and ankle exercises on pain, sleep disturbances, and depression, which are common problems experienced by individuals with diabetic neuropathy.",[28],[281,282,283,284,285,286],"diabetes","neuropathy","Exercise","Pain","Sleep Quality","Depression","2025-12-05",{"date":289,"type":38},"2025-12-18",{"date":291,"type":22},"2025-12-22",{"date":293,"type":22},"2026-06-30",{"name":295,"class":69},"Amasya University",{"id":297,"slug":298,"hasResults":11,"nctId":299,"briefTitle":300,"officialTitle":301,"acronym":4,"eligibilityCriteria":302,"healthyVolunteers":11,"sex":17,"minAge":303,"maxAge":19,"enrollmentInfo":304,"targetDuration":4,"studyType":23,"phases":306,"briefSummary":307,"conditions":308,"keywords":309,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":314,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":320,"locationsCount":70},"100614064","combined-effects-of-inf-and-oep-in-patients-with-diabetic-peripheral-neuropathy-100614064","NCT07274735","Combined Effects of INF and OEP in Patients With Diabetic Peripheral Neuropathy","Combined Effect Of Intraneural Facilitation Therapy And Otago Exercise On Pain, Balance And Quality Of Life In Patients With Diabetic Peripheral Neuropathy","Inclusion Criteria:\n\n* Age 50-75years\n* Both male and female patients will be included in the study\n* Patient with type 2 diabetes mellitus (diagnosed by the physician)\n* Patients with a score ≥ 4 on DN4 scale\n* Patients have a score on the Timed Up-and-Go (TUG) test of less than 15 s\n* Able to walk at least 10 meters long\n\nExclusion Criteria:\n\n* Patient with presence of any other systemic disease rather than diabetes such as end-stage renal failure, uncontrolled hypertension, severe dyslipidemia, chronic liver disease, autoimmune disease, advanced chronic obstructive pulmonary disease etc\n* Patients with documented active alcohol or drug misuse\n* Patient with total or partial amputation of lower extremities\n* Participants will be also excluded if they were morbidly obese or if pregnant (self-reported)\n* Patient with active inflammations or other inflammatory neuropathies including chronic inflammatory demyelinating polyneuropathy, proximal diabetic neuropathy, chemotherapy-induced peripheral neuropathy, autonomic neuropathies, or other neuropathies not associated with DM such as B12 deficiency","50 Years",{"count":305,"type":22},65,[25],"DPN often leads to balance issues, sensory deficits, and chronic pain, which can severely impact daily functioning and independence. INF therapy aims to improve nerve blood flow and alleviate neuropathic symptoms through manual techniques, while the Otago Exercise Program focuses on enhancing strength and balance to reduce fall risk. By comparing these two interventions, this study seeks to identify effective strategies that can improve balance, reduce pain, and enhance the quality of life for individuals suffering from DPN",[28],[310,283,311,312,33],"Diabetic Nephropathies","Musculoskeletal Manipulations","Peripheral Neuropathy","2025-11-28",{"date":315,"type":38},"2025-12-10",{"date":317,"type":38},"2024-10-17",{"date":319,"type":22},"2026-01-17",{"name":166,"class":69},{"id":322,"slug":323,"hasResults":11,"nctId":324,"briefTitle":325,"officialTitle":325,"acronym":4,"eligibilityCriteria":326,"healthyVolunteers":11,"sex":17,"minAge":252,"maxAge":148,"enrollmentInfo":327,"targetDuration":4,"studyType":23,"phases":329,"briefSummary":330,"conditions":331,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":332,"lastUpdatePostDateStruct":333,"startDateStruct":335,"completionDateStruct":337,"leadSponsor":339,"locationsCount":70},"100612948","effect-of-hydrotherapy-on-pain-balance-and-quality-of-life-in-patients-with-diabetic-peripheral-neuropathy-100612948","NCT07260214","Effect of Hydrotherapy On Pain, Balance and Quality of Life in Patients With Diabetic Peripheral Neuropathy","Inclusion Criteria:\n\n* Diagnosis of diabetic peripheral neuropathy due to type 2 diabetes mellitus of both sex Patients must have confirmed diagnosis of diabetic peripheral neuropathy based on clinical symptoms (E.G, numbness, tingling and burning pain) and diagnostic test such as nerve conduction studies\n* Chronicity of type 2 diabetes mellitus more than 10 years\n* Age range: between 40-65years old\n* Stable Blood Glucose Levels HbA1c (≤5.7)\n* No active infections or wound\n\nExclusion Criteria:\n\n* Severe Renal Impairment.\n* Uncontrolled cardiovascular diseases\n* Pregnancy\n* Neurological or musculoskeletal conditions\n* Inability to safely enter or exit the pool\n* Uncontrolled infections\n* Vitamin B12 deficiency.\n* Postural hypotension",{"count":328,"type":22},34,[25],"The current study aims to investigate the effects of hydrotherapy compared to land-based training on patients with diabetic peripheral neuropathy. It will evaluate hydrotherapy's impact on pain relief, sensation improvement, balance, and overall quality of life for these patients.",[28],"2025-11-21",{"date":334,"type":38},"2025-12-03",{"date":336,"type":22},"2025-12-01",{"date":338,"type":22},"2026-03-01",{"name":340,"class":69},"Beni-Suef University",{"id":342,"slug":343,"hasResults":11,"nctId":344,"briefTitle":345,"officialTitle":346,"acronym":4,"eligibilityCriteria":347,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":348,"enrollmentInfo":349,"targetDuration":4,"studyType":229,"phases":4,"briefSummary":351,"conditions":352,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":355,"startDateStruct":357,"completionDateStruct":359,"leadSponsor":361,"locationsCount":70},"100553248","cross-cultural-adaptation-and-validity-of-the-arabic-translated-neuropathy-specific-quality-of-life-questionnaire-100553248","NCT06483620","Cross-cultural Adaptation and Validity of the Arabic-translated NEUROPATHY-SPECIFIC QUALITY OF LIFE Questionnaire","Neuropathy and Foot Ulcer_ Specific Quality of Life Instrument (Neuro QOL) Arabic Version: Cross-cultural Adaptation, Validity, and Reliability for Patients With Type 2 Diabetes","Inclusion Criteria:\n\n* Arabic is their first language The absence of any other neurological diagnosis affecting the sensory and motor system, such as stroke or multiple sclerosis\n* Age ranges between 18 and 70 years,\n* History of DM diagnosed by a physician and confirmed by either hemoglobin A1c ≥6.5% or the use of hypoglycemic agents.\n\nExclusion Criteria:\n\n* A hospital inpatient\n* Had pre-existing comorbidities such as cancer, shingles or other neuropathic pain entity that predated diabetes or can mimic or cause a neuropathic pain that is not arising as a result of diabetes.\n* Pregnant patients as diabetes may be of gestational type\n* Had recently experienced physical trauma that may have contributed to neuropathic pain had trauma or dermatological diseases of the skin as this could affect skin sensitivity (e.g. wounds, psoriasis and eczema).","70 Years",{"count":350,"type":22},290,"PURPOSE: This study will translate, culturally adapt, validate, and test the reliability of the Neuro Qol Arabic version to be used with diabetic patients in Arabic countries.\n\nBackground: The Neuropathy- and Foot Ulcer-Specific Quality of Life instrument is a multidimensional scale was developed to assess the QoL of diabetic patients with peripheral neuropathy. Producing Arabic versions of the Translating Scale can help researchers investigate offloading treatment among the Arabic population with DFUs.\n\nHypotheses: The study design was a cross-cultural validation of NeuroQol, the Arabic version, for patients with DFUs.\n\nResearch Question: Will there be cultural adaptation, validation, and reliability between the (Neuro Qol) Arabic version and the original language?",[353,28],"Diabetic Neuropathies","2025-10-02",{"date":356,"type":38},"2025-10-03",{"date":358,"type":38},"2025-02-13",{"date":360,"type":22},"2026-01-25",{"name":362,"class":69},"Cairo University",{"id":364,"slug":365,"hasResults":11,"nctId":366,"briefTitle":367,"officialTitle":368,"acronym":4,"eligibilityCriteria":369,"healthyVolunteers":11,"sex":17,"minAge":147,"maxAge":19,"enrollmentInfo":370,"targetDuration":4,"studyType":23,"phases":372,"briefSummary":373,"conditions":374,"keywords":375,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":379,"lastUpdatePostDateStruct":380,"startDateStruct":381,"completionDateStruct":383,"leadSponsor":385,"locationsCount":4},"100598736","effect-of-an-exercise-program-on-clinical-aspects-of-people-with-diabetic-peripheral-neuropathy-100598736","NCT07075367","Effect of an Exercise Program on Clinical Aspects of People With Diabetic Peripheral Neuropathy","Effect of a Trunk, Hip, Knee and Ankle Exercise Program on Clinical Aspects of People With Diabetic Peripheral Neuropathy: a Randomized Clinical Trial","Inclusion Criteria:\n\n* Adult individuals aged between 45 and 75 years, male or female, diagnosed with DM2;\n* DPN diagnosis based on vibration sensitivity tests assessed by a 128 Hz tuning fork and tactile sensitivity measured by a 10 g monofilament\n* Sedentary or irregularly active individuals (level A) according to the Physical Activity Level Classification - IPAQ\n* Score of at least 5 points on the Functional Independence Measure (FIM), i.e., requires supervision, but without physical contact\n* Absence of diabetic foot ulcer (DFU) for at least one month\n* No amputation or at most amputation of fingers, except for the hallux\n\nExclusion Criteria:\n\n* Individuals involved in physical training programs simultaneously with the intervention\n* History of surgical intervention in the lower limbs or spine\n* Use of walking assistance devices\n* Diagnosis of severe cardiovascular disorder\n* Diagnosis of other neurological impairments in addition to DPN\n* Presence of dementia or inability to provide consistent information\n* Severe retinopathy",{"count":371,"type":22},64,[25],"Diabetic Peripheral Neuropathy (DPN) is one of the most prevalent and debilitating complications of type 2 diabetes mellitus (DM2), especially affecting the distal region of the lower limbs. Such changes affect clinical aspects, such as quality of life. Several pieces of evidence point to therapeutic exercises as an effective way to minimize these deficits. This is a single-blind randomized clinical trial in which participants will be randomly assigned to two groups. The stipulated sample size was 64 participants. The experimental group will receive a distal\u002Fproximal exercise program and the control group will receive a distal exercise program available in the literature and previously tested. The intervention will last 12 weeks and will take place twice a week, with an average time of 50 minutes. Neuropathic symptoms will be considered primary outcomes. The secondary outcomes evaluated will be: capillary blood glucose, Mini-BESTest, Falls Efficacy Scale (FES), EQ-5D and HADS (depression and anxiety). This study was approved by the local research ethics committee (Opinion 6.802.243), conducted in accordance with the Declaration of Helsinki and in accordance with the CONSORT guidelines.",[28],[86,376,377,157,286,378],"Exercise therapy","Neuropathy symptoms","Anxiety","2025-10-01",{"date":354,"type":38},{"date":382,"type":22},"2026-01-10",{"date":384,"type":22},"2028-01",{"name":386,"class":69},"Federal University of Piaui",{"id":388,"slug":389,"hasResults":11,"nctId":390,"briefTitle":391,"officialTitle":392,"acronym":4,"eligibilityCriteria":393,"healthyVolunteers":11,"sex":17,"minAge":252,"maxAge":19,"enrollmentInfo":394,"targetDuration":4,"studyType":23,"phases":395,"briefSummary":397,"conditions":398,"keywords":401,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":405,"lastUpdatePostDateStruct":406,"startDateStruct":408,"completionDateStruct":410,"leadSponsor":412,"locationsCount":70},"100595772","phase-2-effect-of-melatonin-in-patients-with-diabetic-peripheral-neuropathy-100595772","NCT07036796","Effect of Melatonin in Patients With Diabetic Peripheral Neuropathy","Effect of Melatonin on the Clinical Outcomes in Type 2 Diabetic Patients With Peripheral Neuropathy","Inclusion Criteria:\n\n1. Patients aged 40-75 years diagnosed with type 2 DM.\n2. Diabetes duration at least 1 year.\n3. Patients diagnosed with diabetic peripheral neuropathy.\n4. Stable antidiabetic medication for at least 1 month before enrollment and during the trial\n\nExclusion Criteria:\n\n1. Patients with autoimmune disorders (such as lupus and rheumatoid arthritis), thyroid diseases, peripheral arterial disease and cancer patients.\n2. Patients with severe kidney or liver dysfunction.\n3. Patients diagnosed with neurodegenerative diseases.\n4. Active infection.\n5. Use of medications or supplements known to cause or treat peripheral neuropathy.\n6. Alcohol consumption or substance abuse.\n7. Patients consuming any antioxidant supplements or anti-inflammatory medicines during or 3 months before enrollment.\n8. Pregnancy or lactation or expecting to get pregnant during the study.\n9. Allergy to melatonin.",{"count":102,"type":22},[396],"PHASE2","The aim of the current study is to measure the effect of melatonin as adjunct therapy on oxidative stress, inflammatory markers and clinical outcome in type 2 diabetic patients with diabetic peripheral neuropathy.",[28,399,400],"Diabetic Neuropathy","Diabetic Peripheral Neuropathy in Type 2 Diabetic Patients",[86,402,403,404],"Diabetic neuropathies","Diabetic neuropathy in type 2 diabetes","Melatonin","2025-08-05",{"date":407,"type":38},"2025-08-06",{"date":409,"type":38},"2025-07-04",{"date":411,"type":22},"2026-07-04",{"name":413,"class":69},"Ain Shams University",{"id":415,"slug":416,"hasResults":11,"nctId":417,"briefTitle":418,"officialTitle":419,"acronym":4,"eligibilityCriteria":420,"healthyVolunteers":11,"sex":17,"minAge":147,"maxAge":19,"enrollmentInfo":421,"targetDuration":4,"studyType":23,"phases":422,"briefSummary":423,"conditions":424,"keywords":425,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":429,"lastUpdatePostDateStruct":430,"startDateStruct":432,"completionDateStruct":434,"leadSponsor":436,"locationsCount":4},"100600654","effect-of-an-exercise-program-on-motor-dysfunctions-caused-by-diabetic-peripheral-neuropathy-100600654","NCT07100301","Effect of an Exercise Program on Motor Dysfunctions Caused by Diabetic Peripheral Neuropathy","Effect of a Trunk, Hip, Knee, and Ankle Exercise Program on Motor Dysfunctions Caused by Diabetic Peripheral Neuropathy: a Randomized Clinical Trial","Inclusion Criteria:\n\n* Adult individuals aged between 45 and 75 years, male or female, diagnosed with DM2\n* DPN diagnosis based on vibration sensitivity tests assessed by a 128 Hz tuning fork and tactile sensitivity measured by a 10 g monofilament\n* Sedentary or irregularly active individuals (level A) according to the Physical Activity Level Classification - IPAQ\n* Score of at least 5 points on the Functional Independence Measure (FIM), i.e., requires supervision, but without physical contact\n* Absence of diabetic foot ulcer (DFU) for at least one month\n* No amputation or at most amputation of fingers, except for the hallux\n\nExclusion Criteria:\n\n* Individuals involved in physical training programs simultaneously with the intervention\n* History of surgical intervention in the lower limbs or spine\n* Use of walking assistance devices\n* Diagnosis of severe cardiovascular disorder\n* Diagnosis of other neurological impairments in addition to DPN\n* Presence of dementia or inability to provide consistent information\n* Severe retinopathy",{"count":371,"type":22},[25],"Diabetic Peripheral Neuropathy (DPN) affects approximately half of people with Diabetes Mellitus (DM). Its repercussions on the musculoskeletal system and biomechanics mainly impact balance and locomotor function. Therefore, this study is justified by the need to design effective treatment alternatives for the motor alterations observed in people with DPN. The objective of this study will be to evaluate the effectiveness of an exercise program for the trunk, hip, knee and ankle, consisting of muscle strengthening and sensorimotor training, in the treatment of motor deficits caused by DPN. This will be a single-blind randomized clinical trial in which 64 individuals with type 2 DM and DPN will be randomly distributed between the experimental and control groups. The primary outcome will be the kinematic analysis of gait. The secondary outcomes will be: muscle strength assessed by dynamometry and the 30-second sit-to-stand test (30STS), and functional mobility through the Timed Up and Go (TUG) test. Assessments will be performed before the start of the intervention, at the end of the intervention, and at the one-month follow-up. The experimental group will perform a 12-week proximal\u002Fdistal exercise program (trunk, hip, knee, and ankle). The control group will perform a distal exercise program (ankle and foot). The proposed exercise program is expected to show consistently positive results compared to the control group.",[28],[86,426,156,427,428],"Biomechanic","Muscle strength","Kinematics","2025-07-27",{"date":431,"type":38},"2025-08-03",{"date":433,"type":22},"2025-08",{"date":435,"type":22},"2028-08",{"name":386,"class":69},{"id":438,"slug":439,"hasResults":11,"nctId":440,"briefTitle":441,"officialTitle":442,"acronym":4,"eligibilityCriteria":443,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":444,"targetDuration":4,"studyType":23,"phases":445,"briefSummary":446,"conditions":447,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":449,"startDateStruct":451,"completionDateStruct":453,"leadSponsor":455,"locationsCount":70},"100595136","phase-2-levagen-efficacy-study-on-diabetic-peripheral-neuropathy-100595136","NCT07028528","Levagen+ Efficacy Study on Diabetic Peripheral Neuropathy","A Randomized Placebo Controlled Trial Assessing the Efficacy of Levagen+ for Treating Symptoms of Diabetic Peripheral Neuropathy","Inclusion Criteria:\n\n* Adults aged 18-75 years.\n* Using prescribed glucose-lowering medications, including oral medications (stable dose for 3 months or more) and\u002For insulin for diabetes (type 1 or 2).\n* Scoring12 or more on the Self-reported Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS).\n* Able to provide informed consent.\n* Agree not to change current diet and\u002For exercise frequency or intensity during entire enrolment period.\n* Agree to not participate in another clinical trial during the study period.\n* Able to attend an ACL collection centre.\n\nExclusion Criteria:\n\n* Peripheral neuropathy due to causes other than diabetes mellitus (e.g. nutritional deficiencies; hereditary sensory neuropathy; paraneoplastic diseases; advanced liver disease; kidney disease; hypothyroidism; prolonged phenytoin, warfarin or immunosuppressive drug use; active infection \\[HIV, Lyme disease, Epstein-Barr virus, Hepatitis C, Shingles, Leprosy\\]; autoimmune disease \\[Sjogren syndrome, Lupus, Rheumatoid arthritis, Guillain-Barre syndrome\\]; trauma \u002F injury; toxins \\[heavy metals, chemicals\\]; antibiotics; or inflammatory conditions \\[vasculitis\\]).\n* Serious illness e.g., paraneoplastic diseases, advanced liver disease, kidney disease, hypothyroidism, mood disorders such as depression, anxiety or bipolar disorder, neurological disorders such as MS, or heart conditions, or peripheral vascular disease\n* Unstable illness e.g., diabetes and thyroid gland dysfunction, hypercholesterolemia\n* Current malignancy (excluding Basal Cell Carcinoma) or chemotherapy or radiotherapy treatment for malignancy within the previous 2 years.\n* Currently taking Coumadin (Warfarin), Heparin, Dalteparin, Enoxaparin or other anticoagulation therapy including low dose aspirin\n* Herbal medicines for pain relief including, but not limited to, medicinal cannabis, willow bark (Salix alba), Boswellia (Boswellia serrata) or turmeric\u002Fcurcumin (Curcuma longa).\n* Active smokers, nicotine use or drug (prescription or illegal substances) abuse.\n* Chronic past and\u002For current alcohol use (\\>14 alcoholic drinks per week)\n* Females attempting to conceive, pregnant or lactating\n* Allergic, sensitive or intolerant to any of the ingredients in active or placebo formula.\n* Difficulty swallowing capsules.\n* Participants who are currently participating in any other clinical trial or who have participated in any other clinical trial during the past 1 month.\n* Any condition which in the opinion of the investigator makes the participant unsuitable for inclusion.",{"count":176,"type":22},[396],"The goal of this clinical trial is to assess the efficacy of Levagen+ supplementation for the symptoms of diabetic peripheral neuropathy (DPN) in patients with DPN.\n\nParticipants will have remote visits and attend a local pathology centre for blood draws. They will take the study product for 12 weeks, from baseline to week 12 they will have remote visits every 3 weeks.",[28],"2025-07-21",{"date":450,"type":38},"2025-07-23",{"date":452,"type":38},"2025-07-01",{"date":454,"type":22},"2026-05",{"name":456,"class":457},"RDC Clinical Pty Ltd","INDUSTRY",{"id":459,"slug":460,"hasResults":11,"nctId":461,"briefTitle":462,"officialTitle":463,"acronym":4,"eligibilityCriteria":464,"healthyVolunteers":465,"sex":17,"minAge":147,"maxAge":4,"enrollmentInfo":466,"targetDuration":4,"studyType":23,"phases":468,"briefSummary":469,"conditions":470,"keywords":471,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":448,"lastUpdatePostDateStruct":474,"startDateStruct":476,"completionDateStruct":478,"leadSponsor":480,"locationsCount":70},"100513428","walking-function-in-diabetic-peripheral-neuropathy-100513428","NCT05965336","Walking Function in Diabetic Peripheral Neuropathy","Walking Function in Individuals With Diabetic Peripheral Neuropathy: Biomechanical Mechanisms and Implications for Clinical Outcomes and Gait Retraining","Inclusion Criteria for All Participants:\n\n1. Age 45+ years\n2. Able to walk 10-meters independently without an assistive device\n3. Sufficient cardiovascular and musculoskeletal health to walk on a treadmill for 1-minute at self-selected speed\n\nInclusion Criteria for Participants with DPN:\n\n1. Diagnosis of DM\n2. Diagnosis of DPN by a physician\n3. Foot examination within the past 6 months to document ambulatory status\n4. Physician's clearance\n\nExclusion Criteria for Healthy Able-Bodied Individuals:\n\n1. History of neurologic disease\n2. History of orthopaedic disease affecting the lower extremities\n3. History of injury or pain affecting the lower extremity or walking function within the past 6 months\n\nExclusion Criteria for All Participants:\n\n1. History of amputation\n2. Active ulceration\n3. Medial column deformity\n4. History of Charcot osteoarthropathy\n5. History of posterior muscle group lengthening\n6. History of lower extremity joint replacement\n7. History of lower extremity and\u002For foot surgery affecting walking mechanics\n8. Orthopaedic problems of the lower limbs or spine due to other medical conditions (not DM or DPN) that limit walking or cause pain during walking\n9. Improper footwear for walking and community ambulation\n10. Cardiovascular or medical condition affecting ability to walk safely\n11. History of unexplained dizziness or fainting in the past 2 months\n12. Allergy to adhesive tape or rubbing alcohol\n13. Individuals who are pregnant, prisoners, or not yet adults\n14. Inability to communicate with the investigators\n15. Inability to provide written informed consent",true,{"count":467,"type":22},50,[25],"The purpose of this study is to 1) examine the differences in walking function and movement patterns between individuals with diabetic peripheral neuropathy and healthy adults with no known conditions; 2) examine if receiving feedback on walking form will help change walking patterns; and 3) examine the feasibility, safety, and preliminary effects of walking training with feedback on walking function in individuals with diabetic peripheral neuropathy.",[28],[472,473],"Diabetes","Biofeedback-induced changes",{"date":475,"type":38},"2025-07-24",{"date":477,"type":38},"2024-12-05",{"date":479,"type":22},"2027-03",{"name":218,"class":69},{"id":482,"slug":483,"hasResults":11,"nctId":484,"briefTitle":485,"officialTitle":486,"acronym":4,"eligibilityCriteria":487,"healthyVolunteers":11,"sex":17,"minAge":488,"maxAge":148,"enrollmentInfo":489,"targetDuration":4,"studyType":23,"phases":491,"briefSummary":492,"conditions":493,"keywords":499,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":506,"lastUpdatePostDateStruct":507,"startDateStruct":509,"completionDateStruct":511,"leadSponsor":513,"locationsCount":70},"100591359","effect-of-sensory-training-on-functional-performance-balance-gait-in-type-2-diabetic-individuals-with-neuropathy-100591359","NCT06979401","Effect of Sensory Training on Functional Performance, Balance, Gait in Type 2 Diabetic Individuals With Neuropathy","Effects of Foot Sensory Training on Plantar Sensation, Functional Performance, Balance, Gait and Kinesiophobia in Type 2 Diabetic Individuals With Neuropathy","Inclusion Criteria:\n\n* Being 35-65 years old\n* Being diagnosed with type 2 diabetes\n* Having achieved glycemic control\n* Having given less than 8 correct answers in the Semmes-Weinstein Monofilament test performed with a 5.07 monofilament\n* Getting a Neuropathy Disability Score of 3 and above\n* Being willing to participate in the study\n* Being literate\n\nExclusion Criteria:\n\n* Having a neurological or orthopedic comorbidity\n* Having a respiratory disease such as uncontrolled COPD or asthma\n* Having active lower extremity ulceration\n* Using medications known to affect the postural control system such as benzodiazepines\n* Having nephropathy, retinopathy and diabetic arthritis at a level that may affect mobility in addition to neuropathy\n* Using a walking aid\n* Body Mass Index \\>30\n* Having communication problems\n* Not participating in at least 3 consecutive exercise sessions\n* Not participating in more than 30% of each session","35 Years",{"count":490,"type":22},40,[25],"Diabetic peripheral neuropathy (DPN) is a common complication of type 1 and type 2 diabetes. DPN is characterized by significant axonal degeneration and segmental demyelination affecting sensory and motor nerves. The effect of foot sole sensation on gait and balance parameters has been reported in various studies in the literature, however, no study has been found examining the effect of foot sensory training on plantar sensation, functional performance, balance, gait and kinesiophobia in type 2 diabetic individuals with neuropathy. In order to contribute to the literature, 40 type 2 diabetic individuals with neuropathy who applied to the Turgut Ozal Medical Center Endocrinology and Metabolic Diseases Polyclinic will be included in this randomized controlled study. After diabetic foot training is given to all participants, an experimental (20) and a control (20) group will be formed with a sequential random method. Foot sensory training will be given to the experimental group, while no intervention will be made to the control group, and sensory training will be given to the participants who wish after the study is completed. All participants will be evaluated for subscapular sense, functional performance, balance, walking and kinesiophobia at the beginning and end of the training. Subscapular sense will be evaluated with light touch, two-point discrimination and vibration tests. Functional performance evaluation will be made with timed up and go test and timed stair ascent-descend test. Kinesiophobia will be analyzed with Tampa Kinesiophobia Scale, Balance; One-Legged Stand Test and Y balance tests and walking will be analyzed with Kinect V2 camera based software. Physical activity levels will be evaluated with International Physical Activity Questionnaire-Short Form. The data taken into the research will be analyzed with SPSS (Statistical Program in Social Sciences) program. The values belonging to the data will be expressed with percentage, mean and standard deviation, and the significance level (p) will be taken as 0.05 for comparison tests.",[472,494,28,495,155,496,497,498],"Type 2 Diabetes","Kinesiophobia","Functional Performance","Gait Analysis","Plantar Sensation",[500,498,501,502,503,504,505],"balance","type 2 diabetes","gait","kinesiophobia","functional performance","diabetic peripheral neurophaty","2025-05-16",{"date":508,"type":38},"2025-05-19",{"date":510,"type":22},"2025-06-15",{"date":512,"type":22},"2025-12-15",{"name":514,"class":69},"Aylin DEMİR",{"id":516,"slug":517,"hasResults":11,"nctId":518,"briefTitle":519,"officialTitle":520,"acronym":521,"eligibilityCriteria":522,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":148,"enrollmentInfo":523,"targetDuration":4,"studyType":23,"phases":524,"briefSummary":526,"conditions":527,"keywords":528,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":530,"lastUpdatePostDateStruct":531,"startDateStruct":533,"completionDateStruct":535,"leadSponsor":537,"locationsCount":4},"100552941","phase-4-the-effect-of-piracetam-on-diabetic-peripheral-neuropathy-patients-100552941","NCT06479629","The Effect of Piracetam on Diabetic Peripheral Neuropathy Patients","The Effect of Piracetam on the Clinical Outcomes of Diabetic Patients with Peripheral Neuropathy","DPN","Inclusion Criteria:\n\n1. Adults (\\>the age of 18).\n2. Established diagnosis of type 2 Diabetes Mellitus.\n3. Patients receiving insulin therapy.\n4. Stable regimen for at least 3 months prior to inclusion in the study\n5. HbA1C\\>7.5%\n\nExclusion Criteria:\n\n* Patients with inadequate hepatic function Alanine aminotransferase, Aspartate aminotransferase (ALT, AST \\> or equal to 3 times upper normal limit).\n* Patients with myopathy, epilepsy, malignancy, unstable psychiatric illness, bleeding tendency, or peripheral vascular diseases.\n* Patients with an estimated Glomerular Filtration Rate (GFR) Less than 45 ml\u002Fmin and albumin\u002Fcreatinine ratio or urea to creatinine \\>30.\n* Patients with any conditions that could confound pain assessment (for ex: other severe pain or skin conditions in the area affected by neuropathy.\n* Cognitive or language difficulties that would impair understanding\u002Fcompletion of the assessment instruments.\n* Presence of foot ulcers.\n* Causes of neuropathy other than diabetes and significant neurological diseases.\n* Pregnant and\u002For breastfeeding women.\n* Use anticonvulsants, antidepressants, membrane stabilizers, and opioids.\n* Patients with a history of Substance use and alcohol abuse,\n* Patients with a history of (cerebral hemorrhage) or at risk of blood diseases.\n* Patients allergic to piracetam",{"count":102,"type":22},[525],"PHASE4","Aim of the work:\n\nTo evaluate efficacy and safety of Piracetam in Diabetic patients with peripheral neuropathy.\n\nScientific background:\n\nDiabetes mellitus (DM) is known to precipitate various neurologic complications, with diabetic neuropathy (DN) emerging as a significant microvascular consequence affecting both type 1 and type 2 diabetes mellitus (T2DM) patients. Notably, diabetic neuropathy can manifest even at the onset of type 2 diabetes mellitus. Peripheral neuropathy stands as the most common subtype of diabetic neuropathy, impacting nearly half of all individuals with diabetes over their lifetimes, as per recent guidelines. The development of diabetic neuropathy (DN) involves various metabolic and cellular processes, including inflammation and oxidative stress. Inflammation, characterized by cytokines and inflammatory cells, plays a role in diabetic neuropathy progression. Reactive oxygen species (ROS) contribute significantly, with low levels of antioxidants exacerbating the condition. Accumulation of advanced glycation end products (AGEs) further damages nerves. diabetic neuropathy leads to significant pain and discomfort for patients, yet current treatments often fall short of expectations. Improving treatment strategies is crucial to relieve suffering and improve the well-being of those affected by diabetic neuropathy. Piracetam shows promise in managing diabetic neuropathy (DN) based on both preclinical and clinical studies. It may enhance central nervous system function by influencing neurotransmitter release, potentially alleviating diabetic neuropathy symptoms. Additionally, piracetam's neuroprotective properties could shield nerve cells from oxidative stress and inflammation, which are key contributors to diabetic neuropathy nerve damage.",[28],[472,312,529],"Piracetam","2025-01-27",{"date":532,"type":38},"2025-01-28",{"date":534,"type":22},"2025-02-10",{"date":536,"type":22},"2025-11-01",{"name":413,"class":69},{"id":539,"slug":540,"hasResults":11,"nctId":541,"briefTitle":542,"officialTitle":543,"acronym":4,"eligibilityCriteria":544,"healthyVolunteers":11,"sex":17,"minAge":303,"maxAge":19,"enrollmentInfo":545,"targetDuration":4,"studyType":23,"phases":547,"briefSummary":548,"conditions":549,"keywords":550,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":555,"lastUpdatePostDateStruct":556,"startDateStruct":558,"completionDateStruct":560,"leadSponsor":561,"locationsCount":562},"100567091","intraneural-facilitation-therapy-and-nerve-flossing-technique-in-patients-with-diabetic-peripheral-neuropathy-100567091","NCT06663670","Intraneural Facilitation Therapy and Nerve Flossing Technique in Patients With Diabetic Peripheral Neuropathy","Comparative Effects of Intraneural Facilitation Therapy and Nerve Flossing Technique on Pain, Balance, Gait, and Quality of Life in Patients With Diabetic Peripheral Neuropathy","Inclusion Criteria:\n\n* Type 2 diabetes mellitus (diagnosed by the physician)\n* Score \\>3 on Michigan Neuropathy Screening Instrument-Questionnaire and score \\>2 on MNSI-Physical Examination\n* Diabetic peripheral neuropathy symptoms below the ankle (numbness, tingling, burning, sharp pain, increased sensitivity, etc.)\n\nExclusion Criteria:\n\n* Presence of any other systemic disease rather than diabetes such as end-stage renal failure, uncontrolled hypertension, severe dyslipidemia, chronic liver disease, autoimmune disease, advanced chronic obstructive pulmonary disease, etc.\n* Diabetic ulcer in either foot\n* Total or partial amputation of lower extremities\n* Active inflammations or other inflammatory neuropathies including chronic inflammatory demyelinating polyneuropathy, proximal diabetic neuropathy, chemotherapy-induced peripheral neuropathy, autonomic neuropathies, or other neuropathies not associated with DM such as B12 deficiency\n* History of fracture, strain, history of trauma leading to nerve injuries in the last year.",{"count":546,"type":22},44,[25],"The aim of this study is to determine the comparative effects of intraneural facilitation therapy and nerve flossing technique on pain, balance, gait, and quality of life in Diabetic peripheral neuropathy.",[28],[551,399,552,553,156,284,554,33],"Diabetes mellitus Type 2","Endoneurium","Epineurium","Peripheral Nerve","2024-11-25",{"date":557,"type":38},"2024-11-26",{"date":559,"type":22},"2024-12",{"date":433,"type":22},{"name":166,"class":69},2,{"id":564,"slug":565,"hasResults":11,"nctId":566,"briefTitle":567,"officialTitle":567,"acronym":568,"eligibilityCriteria":569,"healthyVolunteers":465,"sex":17,"minAge":252,"maxAge":348,"enrollmentInfo":570,"targetDuration":4,"studyType":229,"phases":4,"briefSummary":572,"conditions":573,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":576,"lastUpdatePostDateStruct":577,"startDateStruct":579,"completionDateStruct":581,"leadSponsor":583,"locationsCount":70},"100556042","muscle-and-bone-in-patients-with-diabetes-mellitus-and-neuropathy-100556042","NCT06519942","Muscle and Bone in Patients with Diabetes Mellitus and Neuropathy","SVT-DNP","Inclusion Criteria:\n\nAll participants:\n\n* Between 40-70 years of age\n* BMI between 18,5 - 35 kg\u002Fm2\n\nPersons with T2DM:\n\n* More than 10-year clinical diagnosis of T2DM\n\nExclusion Criteria:\n\nAll participants:\n\n* Possible other causes of nerve impairment (vitamin B12 deficiency, excessive alcohol consumption, chemotherapy)\n* Immobilisation (1) \\> 3 months in past history or (2) \\> 4 weeks in past 6 months\n* Chronic conditions affecting the vital organs (New York Heart Association (NYHA) 3\u002F4, Global Initiative for Obstructive Lung Disease (GOLD) 3\u002F4, cystic fibrosis)\n* Hypogonadism\n* Inflammatory joint or intestinal diseases\n* Chronic muscle diseases\n* Active malignancy\n* Malnutrition disease, eating disorder or bariatric surgery\n* Medication use (anticoagulants, glucocorticoids, anti-androgen or anti-estrogen treatment) persons with T2DM:\n* Insufficient control of diabetes (HbA1c \\>9%)\n\nHealthy controls:\n\n* Fasting glucose \\> 100 mg\u002Fdl\n* HbA1c \\> 5.7 %",{"count":571,"type":22},145,"The goal of this observational study is to evaluate muscle fiber type composition in people with type 2 diabetes mellitus (T2DM) with a common complication of T2DM: diabetic peripheral neuropathy (DNP), specifically diabetic sensorimotor polyneuropathy. Researchers will also look into factors related to DNP: inflammation, the use of energy in the cell, nerve function and the tiny blood vessels in the muscle.\n\nThe main question it aims to answer is: Are there differences in muscle fiber type composition between persons with T2DM with and without DNP, in comparison to sex and age-matched healthy peers?\n\nParticipants will partake in the following tests:\n\n* electromyoneurography (EMNG): evaluation of nerve function, damage and repair; for diagnosis of DNP or other diseases of the nerves\n* blood analysis: researchers will measure insulin, blood sugar, lipid profile, inflammation\n* muscle biopsy in the calf (m. gastrocnemius): a doctor will take a small sample of muscle to evaluate the muscle shape and structure\n* mechanography: patients will perform functional tests (e.g. standing up from a chair), researchers will evaluate maximal power and maximal force of the muscles by jumping tests\n* questionnaires: on food intake, physical activity, smoking history, alcohol use, medical history\n* measurement of height, weight, and the comparison of the hip and waist circumference\n* peripheral Quantitative Computed Tomography (pQCT): scan of the calf for muscle density and bone density\n* electrocardiography (ECG): evaluation of electrical signals of the heart\n\nResearchers will compare (1) patients with T2DM with DNP, (2) patients with T2DM without DNP, and (3) healthy persons to see if there are differences in muscle fiber type composition",[574,28,575],"Diabetes Mellitus, Type 2","Sarcopenia","2024-09-05",{"date":578,"type":38},"2024-09-19",{"date":580,"type":38},"2023-12-12",{"date":582,"type":22},"2025-11",{"name":584,"class":69},"University Hospital, Ghent",{"id":586,"slug":587,"hasResults":11,"nctId":588,"briefTitle":589,"officialTitle":589,"acronym":521,"eligibilityCriteria":590,"healthyVolunteers":465,"sex":17,"minAge":303,"maxAge":591,"enrollmentInfo":592,"targetDuration":4,"studyType":23,"phases":593,"briefSummary":594,"conditions":595,"keywords":599,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":607,"lastUpdatePostDateStruct":608,"startDateStruct":610,"completionDateStruct":612,"leadSponsor":614,"locationsCount":70},"100557958","balance-control-and-recovery-in-diabetes-peripheral-neuropathy-100557958","NCT06544876","Balance Control and Recovery in Diabetes Peripheral Neuropathy","Inclusion Criteria:\n\n* Type II diabetes with peripheral neuropathy\n\nExclusion Criteria:\n\n* Foot ulcer\n* Partial amputation\n* Have experience of Stroke\n* Painful neuropathy\n* Inability to stand or walk independently","99 Years",{"count":102,"type":22},[25],"In this study the effects of diabetic peripheral neuropathy will be assessed on balance control, balance recovery, and muscle electrical activity in adults over 50 years.\n\nAim 1: Determine muscle activity and balance control during a sit-to-stand in adults age above 50 with and without diabetic peripheral neuropathy.\n\nAim 2: Assess local balance recovery and latency responses to lateral surface perturbation during quiet standing.",[28,596,597,598],"Diabetic Peripheral Neuropathy Type 2","Diabetic Peripheral Neuropathy Type 2 - Uncontrolled","Healthy Aging",[209,500,600,601,602,603,604,605,606],"sensation","aging","older adult","foot","sit-to-stand","falls","falling","2024-08-05",{"date":609,"type":38},"2024-08-09",{"date":611,"type":38},"2023-09-12",{"date":613,"type":22},"2028-08-31",{"name":615,"class":69},"Lisa Griffin",{"id":617,"slug":618,"hasResults":11,"nctId":619,"briefTitle":620,"officialTitle":621,"acronym":622,"eligibilityCriteria":623,"healthyVolunteers":465,"sex":17,"minAge":624,"maxAge":625,"enrollmentInfo":626,"targetDuration":4,"studyType":229,"phases":4,"briefSummary":627,"conditions":628,"keywords":631,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":636,"lastUpdatePostDateStruct":637,"startDateStruct":639,"completionDateStruct":641,"leadSponsor":643,"locationsCount":70},"100382303","proteomic-analysis-in-paediatric-diabetes-type-1-papd-100382303","NCT04257877","Proteomic Analysis in Paediatric Diabetes Type 1 (PAPD)","Targeted Proteomic Analysis in the Plasma of Children With Diabetes Type 1 and Its Association With Peripheral Diabetic Neuropathy","PAPD","Inclusion Criteria:\n\n1. Children with confirmed DT1 under insulin substitution therapy\n2. Age 5-10 years\n3. Good glycemic control with HbA1c ≤ 7.0%\n4. Prepubertal patients\n5. Absence of other diseases\n6. Signed informed consent of the parents or guardians of patients\n\nExclusion Criteria:\n\n1. Presence of organic cause for neuropathy\n2. Presence of other chronic disease\n3. Poor glycemic control\n\n3\\. Medication","5 Years","10 Years",{"count":467,"type":22},"The aim of the present study is to investigate a targeted proteomic analysis in plasma of children - of Greek origin- with type 1 diabetes (DT1) and its correlation with the electrophysiological findings that accompany diabetic peripheral neuropathy.\n\nDiabetic neuropathy is the most frequent chronic complication in adults with DT1 and rarely appears in childhood. Nevertheless, cases of acute mononeuritis have been described at the time of diagnosis of DT1. According to recent reports several biomarkers, including proteomic analysis, have been proposed for the early detection of peripheral neuropathy in children and young adults with T1DM.\n\nIn the present study the researchers will attempt to investigate the role of biomarkers with targeted proteomic analysis in the plasma of children with DT1 in combination with an electrophysiological study, which includes a nerve conduction study, to detect early diabetic peripheral neuropathy, before the appearance of clinical manifestations.",[629,630,28],"Diabetes Type 1","Proteomics",[632,633,634,635],"plasma proteomics","children","diabetes type 1","nerve conduction","2024-07-29",{"date":638,"type":38},"2024-07-31",{"date":640,"type":38},"2018-11-20",{"date":642,"type":22},"2025-01-20",{"name":644,"class":69},"Aristotle University Of Thessaloniki"]